Approximately 20-30% of patients with metastatic germ cell cancers (GCCs) can develop relapsed or refractory (RR) disease, about 40-50% of patients who relapse after salvage chemotherapy may reach long-term remission. The goal of this review was to identify patients who appear to benefit from high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). To access this, we performed a systematic medical literature review to evaluate the effectiveness of HDCT in the frontline setting, as well as in patients with RR testicular cancer. We searched databases for interventional clinical studies and identified 5883 studies. We selected 49 studies for inclusion, which included a total of 5985 patients. Seventeen studies reported results of newly diagnosed poor-risk GCC patients and 32 studies reported results of RR patients. For newly diagnosed patients with poor prognostic predictors, a risk adjusted strategy using unfavorable tumor marker decline with initial standard chemotherapy regimen and upfront HDCT demonstrated improved outcomes. Our data suggest a minimum of two HDCT cycles with ASCT should be standard of care for patients with RR GCC. Failure of HDCT results in a poor prognosis with only 10% of patients achieving lasting remission with salvage therapy.
Background
Testicular cancer is a rare disease primarily affecting young men between the ages of 15 and 40 years. An estimated 8000 patients received a new diagnosis of testicular cancer in United States in 2016. The worldwide incidence of testicular cancer is 1.5 per 100,000 [1, 2] . The development of effective platinum-containing chemotherapy, such as combination cisplatin, etoposide and bleomycin (BEP), has increased the cure rate for testicular germ cell cancers (GCCs) [3] . Even advanced GCC can be cured in a majority of cases (>80%) [4] with frontline conventional dose chemotherapy (CDCT) combinations containing platinum such as cisplatin, etoposide (EP), BEP and etoposide, ifosfamide and cisplatin (VIP). Adjunctive surgery is routinely used for anatomically resectable residual tumors to enhance the cure rate. In spite of adequate first-line treatment, 15-25% of germ cell tumor (GCT) patients may relapse. In all, 40-50% of patients who relapse after first-line standard-dose cisplatin-based combination salvage chemotherapy like TIP (paclitaxel, ifosfamide, and cisplatin) or VeIP (vinblastine, ifosfamide, cisplatin) may reach long-term remission [5] [6] [7] .
Investigators in the International Germ Cell Cancer Collaborative Group (IGCCCG) found that metastatic GCCs in the poor-risk group (Table 1) have 50% estimated cure rates [8] . The IGCCCG classified the metastatic non-seminomatous germ cell tumors (NSGCTs) as favorable (60% of GCT with a 91% 5-year survival), intermediate risk (26% of GCT with a 79% 5-year survival) and poor-risk groups (14% of GCT with 48% 5-year survival) with estimated cure rates of 90, 80 and 40-50%, respectively [9] . After realization of limitations of CDCT [10, 11] , high-dose chemotherapy (HDCT) followed by rescue autologous stem cell transplant (ASCT) was studied in the IGCCG poor-risk group patients in the frontline setting [12, 13] , as well as in relapsed and refractory (RR) GCC cases [6, 14] . HDCT can achieve better results with a 2-year progression-free survival (PFS) of 63% (when given as second-line therapy), and 49% (as third-line therapy or later) [15] . There is an ongoing international randomized multicenter open label phase III (TIGER) trial to assess the impact of sequential HDCT given at first relapse compared with conventional dose standard chemotherapy on patients' overall survival (OS) and PFS [16] . In an attempt to identify patients who benefit most from HDCT, we conducted a systematic review of published literature looking at phase II and III trials studying the role of one, two or three cycles of HDCT along with ASCT HDCT in frontline setting and relapsed refractory GCC.
Materials and methods

Objective of the study
We systematically analyzed germ cell therapy trials with the goal of providing evidence for the efficacy of HDCT in the treatment of GCC. Our goal was to identify patient characteristics and high-dose regimens that are less effective in order to avoid unnecessary exposure to toxic chemotherapy. We focused on four specific research questions and tried to answer these specific questions through the review of published literature (Table 2) .
Eligibility criteria
All clinical trials studying the role of HDCT followed by stem cell transplant in poor-risk or relapsed refractory GCTs were included. We found 5883 studies, after removing duplicates, we were left with 4400 studies. We screened the titles and abstracts of 4400 studies and based on non-relevance excluded 3872 studies. We read the fulllength articles of 528 studies and included 49 studies in our review. We excluded 479 studies based on following reasons (review, opinion, editorial, non-original study, studies published in multiple journals based on the exact same data). If a study was published after long-term follow up, earlier versions of abstracts and studies were excluded. 
Study selection and date collection process
We included only English language studies in our review article. References of the included studies were hand searched to ensure that we did not miss any eligible studies. Four researchers (MU, AI, AJ and SA) independently reviewed these studies and reached to a common studies after detailed discussion. We abstracted data in an excel sheet using a structured template.
Data synthesis and analysis
Due to wide heterogeneity among trials, we did not perform a quantitative meta-analysis, but rather focused on presentation of data qualitatively corresponding to each of the four objectives stated in Table 2 .
Outcome measures
The primary outcome measures included complete remission (CR), OS and PFS for high-risk patients without relapse (Table 3 ). Table 4 summarizes the effect of HDCT in poor-risk GCC patients with poor tumor marker decline. Tables 5 and 6 summarize relapsed patients treated with carboplatin-etoposide (CE)-based regimens and Table 7 looks at relapsed patients on non-CE-based regimens. We categorized patients as having poor disease marker decline if both alpha fetoprotein (AFP) and β-human chorionic gonadotrophin (β-HCG) did not decline to normal by the start of cycle 3 or had a half-life >7 days for AFP or >3.5 days for HCG [17] .
Results
Study selection
HDCT studies were divided into two broad categories: (1) newly diagnosed poor-risk GCCs and (2) relapsed and or refractory GCCs. Our comprehensive literature search, which was last updated on 28 April 2017, yielded 5869 studies (Fig. 1 , PRISMA flow chart). After screening, Table 2 Four key questions and their answers to address role of HDCT for GCC
Questions
Answers
Will frontline use of high-dose chemotherapy consolidation in IGCCG high-risk patients without disease relapse lead to better outcomes?
Most of randomized controlled trials failed to demonstrate significant benefit of HDCT over CDCT in frontline setting.
What is the evidence for the use of unsatisfactory tumor marker decline as a screening criterion for selecting newly diagnosed patients who have primary platinum refractory disease and will benefit from HDCT?
When patients were randomized for receiving HDCT vs CDCT using unsatisfactory marker decline, among platinum refractory patients unsatisfactory marker decline was predictive of poor outcome but best regimen is not well established for this population.
For relapsed and refractory GCC, whether a CE-based therapy is superior over a non-CE-based regimen?
Published literature indicates CE-based single transplant did not improve outcomes and shouldn't be offered. While using two cycles of HD CE has a positive role in treating platinum refractory or relapsed patients.
What is the evidence for the newly adopted approach of three cycles of HDCT with three cycles of autologous rescue for relapsed or refractory GCC?
Studies show three cycles of high-dose CE-based therapies just like two cycles of HD CE, improved survival in treating platinum refractory or relapsed patients.
HDCT high-dose chemotherapy, CDCT conventional dose chemotherapy, GCC germ cell cancers, CE cisplatin, etoposide,
we selected a total of 48 studies for inclusion in the study. A total of 5985 patients were included taken from 17 studies [12, 13, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] containing 1777 patient's data for the newly diagnosed poor-risk GCT group and 32 studies [10, 14, 15, containing data for 4208 patients with relapsed and or refractory group.
Study characteristics
In our first category, HDCT as a therapeutic option to overcome poor prognostic factors in newly diagnosed GCC patients were targeted. Six randomized phase III studies [13, 18, 21, [29] [30] [31] are summarized in Tables 3 and 4 . Four randomized phase II studies [12, 19, 20, 32] are summarized in Table 3 , as well as seven non-randomized single arm phase II studies [22] [23] [24] [25] [26] [27] [28] . The role of high-dose therapy in RR patients with one cycle of CE-based regimen in a phase III randomized trial [58] and with two cycles of CE-based regimens in eight non-randomized clinical trials [10, 15, 36, 42, 43, [53] [54] [55] are summarized in Table 5 . Seven studies using three cycles of high-dose therapy with autologous stem cell rescue and salvage paclitaxel plus ifosfamide followed by carboplatin plus etoposide (TI-CE regimen) has been summarized [45, 47-50, 56, 62] in Table 6 . We included 11 studies [33, 34, 37, 41, 44, 51, 52, 57, [59] [60] [61] regarding RR GCC patients treated with non-CE based regiments and one cycle of high-dose therapy. In Table 7 , we summarized the results of five studies [14, 35, [38] [39] [40] regarding RR GCC patients treated with non-CE-based regimens and two or more cycles of high-dose therapy with ASCT. We summarized the criteria for defining high risk, intermediate risk and good risk using IGCCCG classification in Table 1 [17] .
Efficacy of the interventions
HDCT in frontline setting
In the high-risk frontline therapy group, most of the randomized trials failed to show any significant benefit with HDCT (Table 3) . A subgroup analysis for marker unsatisfactory decline patients (n = 67) by Motzer et al. [13] showed that the outcome was better in the cohort of patients who changed treatment to HDCT when compared with patients who continued conventional BEP chemotherapy. The 1-year durable CR was 61 vs 34% (p = 0.03), and 2-year survival rate of 78 vs 55% (p = 0.02), favoring HDCT in this subgroup emphasizing that frequent serum marker determination during the first two cycles of BEP chemotherapy is predictive of response. Bokemeyer et al. [20] conducted a matched-pair analysis comparing frontline HDCT with VIP therapy with CDCT cisplatin, etoposide, and bleomycin (PEB) or VIP chemotherapy. Multivariate analysis demonstrated HDCT to be significantly superior to CDCT when adjustments were made for prognostic factors (p = 0.021). We found 2-year PFS (75 vs 59%) and OS (82 vs 71%) to be significantly prolonged in the HDCT group (p = 0.0056 and p = 0.0184, respectively).
Four studies (summarized in Table 4 , two phase II and two phase III) utilized unsatisfactory tumor marker decline for selecting newly diagnosed patients for HDCT. GETUG 13 (Genito-urinary tumor group), a multicenter phase III randomized trial by Fizazi et al. [29] randomized 263 patients into either the BEP group or a dose-dense regimen based on unfavorable tumor marker decline after one cycle of BEP. The 3-year PFS rate was 59% in the HDCT arm vs 48% in the CDCT arm. The 3-year OS was 73 vs. 65%, respectively. Study authors concluded that using high dense chemotherapy based on tumor marker decline reduces the relative risk of progression or death by 34%. Findings of GETUG 13 along with subgroup analysis from phase III trial data by Motzer et al. [13] provides us evidence for the management of patients with IGCCCG poor-risk GCC based on tumor marker decline. Personalized treatment based on tumor marker decline assessed after one cycle of chemotherapy in upfront treatment of GCTs identifies patient's risk of progression or death.
HDCT in RR group
Eleven studies with prospective or retrospective data in this category showed a great deal of heterogeneity in the patient subgroups and variability in the intervention. Pico et al. [6] in a randomized Phase III trial conducted on behalf of the European group for blood and marrow transplantation (EBMT) concluded that a single cycle of high-dose salvage chemotherapy after three cycles of standard-dose chemotherapy offered no additional positive impact (p = 0.16) on treatment outcomes and should not be offered [61] . Lorch et al. [58] concluded that there was a benefit of sequential HDCT compared with conventional chemotherapy but their study was a non-randomized retrospective comparative analysis.
In Table 5 , we summarized eight studies using two cycles of high-dose CE therapy, most of which showed improved long-term survival and PFS confirming that CE has a positive role in treating relapsed refractory patients.
Seven studies reviewing the use of three cycles of high-dose therapies (TICE) in RR setting, showed improved survival and PFS while only two earlier studies, Motzer et al. phase 1 [62] , and Lotz et al. phase II [45] failed to demonstrate improved outcomes (Table 6 ). In Table 7 , we summarized non-CE-based therapy in 16 studies, including three randomized trials, showing no evidence of benefit [14, 57, 61] . In conclusion, the data in Tables 3 and 4 show that among newly diagnosed high-risk patients, there is limited benefit of HDCT and patients with unsatisfactory marker decline many benefit from HDCT but optimum therapy in this setting is not well established. Based on the evidence from our analysis, we conclude that single cycle of high-dose salvage chemotherapy offers no benefit and should not be used. Two or three cycles of HD CE plays a positive role in treating platinum refractory or relapsed patients. 
Discussion
For newly diagnosed GCC patients treated with conventional chemotherapy, reported cure rates for good, intermediate and high-risk metastatic GCTs are 90, 84 and 51%, respectively [15] . For high risk of relapse or poor prognosis IGCCCG patients, use of a frontline HDCT regimen has shown negative results in three large randomized studies (n = 445) [13, 18, 30] . Three studies (n = 321) selected patients for HDCT based on unsatisfactory decline of serum markers after limited (1-2) cycles of CDCT, and treated these patients with HDCT. Motzer et al. [13] , in their phase III trial (n = 209), found in a subgroup analysis of limited number of patients (n = 67) with primary platinum refractory disease marked by slow serum tumor marker decline (AFP and/or HCG) during the first two cycles of chemotherapy had a shorter PFS (p = 0.02) and OS (p = 0.03) when compared with patients with satisfactory marker decline. Motzer et al. defined marker decline as satisfactory if both AFP and HCG demonstrated decline to normal by the start of cycle 3 or had a half-life ≤7 days for AFP and ≤3.5 days for HCG or if one marker had a satisfactory decline and the other was not elevated at baseline. The marker decline was unsatisfactory if one or both markers demonstrated a slow decline (half-life ≥7 days for AFP or ≥3.5 days for HCG). Among the unsatisfactory marker decline group, the 1-year durable complete response proportion was 61% with HDCT vs 34% for patients receiving conventional BEP alone (p = 0.03) [13] . Fizazi et al. [29] randomized their patients to a dose-dense regimen based on unfavorable tumor marker decline after one cycle of BEP. Based on superior 3-year PFS rate (59% in the HDCT arm vs 48% in the CDCT BEP arm) and 3-year OS (73% HDCT vs 65 % in CDCT), authors concluded that using dose-dense chemotherapy guided by slow tumor marker decline reduces the relative risk of progression or death by 34%. Based on phase III studies, four cycles of conventional BEP regimen remains standard of care for metastatic disease, inadequate tumor marker decline after first cycle has a predictive role, it correlates with decreased survival after four cycles of BEP. Critics [63] think important question about the optimum regimen was unanswered by GETUG trial and pointed out multiple limitations, which included use of an unusually Table 6 Studies using high-dose CE with three transplants in relapsed or refractory GCC setting Tables 3, 4 and 5 for summary results of CDCT and HDCT for relapsed GCC patients. Through extensive review of literature for treatment of relapsed refractory GCC, we found that a regimen consisting of highdose CE is preferred if no randomized prospective clinical trial is available. There is no direct comparison between the Indiana regimen [42] and the TI-CE regimen. The Indiana regimen consists of two cycles of HDCT with carboplatin, etoposide, whereas the TI-CE regimen consists of a relatively lower dose of three cycles of HDCT followed by autologous peripheral stem cell rescue. We conclude that using either of these two CE-based regimens with a minimum of two HDCT cycles and autologous peripheral blood stem cell rescue is the current standard. Differences among these CE-based regimens include, with TI-CE regimen, using preparative chemotherapy (cycles 1 and 2) before stem cell collection in all patients, administering three rather than two high-dose cycles, which are given with Indiana regimen. Dosing of carboplatin is by target AUC in TI-CE, body surface area is used for dose calculation in case of Indiana regimen. TI-CE regimen does not use adjuvant oral etoposide following HDCT, which is done with Indiana regimen. There is a suggestion of overcoming platinum resistance with TI-CE regimen in patients with platinum resistance. With comparable promising results and lower toxicity than traditional HDCT, we conclude that TI-CE is acceptable as an equally good option for the current standard of care. In a phase II study, carboplatin dose was individualized for patient by using therapeutic drug monitoring in order to reach the target AUC of 24 mg/min/ ml over 3 days [64] . Based on the efficacy data on HDCT, no subgroup of patients, including patients with mediastinal primaries, should be excluded from consideration of HDCT.
Based on current data, a single cycle of HDCT following conventional salvage therapy cycles is not beneficial and should not be done as planned therapy. Addition of a third agent such as thiotepa, cyclophosphamide or ifosfamide to CE-based HDCT regimen is not beneficial. Cyclophosphamide-based mobilizations did not show any additional benefit but it can increase the avoidable toxicity of HDCT. Peripheral blood stem cell dose consisting of a minimum of 1 × 10 6 CD34+ cells/kg, per Indiana University investigators can lead to satisfactory engraftment. Peripheral blood stem cell mobilization is done with the first two cycles of conventional salvage chemotherapy with granulocyte colony-stimulating factor (G-CSF) support in the TI-CE regimen and by using G-CSF alone in the Indiana regimen.
HDCT is curative for only half of relapsed patients, there is an urgent need to use precision and personalized medicine based molecular studies and next-generation sequencing to identify and utilize novel targets and agents in clinical studies that can identify patient subsets who will benefit from targeted therapy. Even patients with relapsed GCC with progressing brain metastasis are curable with HDCT [65] . There is emerging data for actionable targets such as CD30 among GCC [66] . Targeted therapy using specific antibodies, agents like sunitinib, imatinib, brentuximab vedotin, check point inhibitors, and anti-CD 105 antibody need to be tested based on individual patient profile [67] [68] [69] [70] . Limitations of our analysis include heterogeneity among included studies based on the study population, risk stratification, dose and nature of chemotherapy regimens. Therefore, the results and conclusions require careful interpretation when deriving inferences from this systematic review.
In conclusion, there is no benefit of HDCT over CDCT in the frontline setting, inadequate tumor marker decline after first cycle of chemotherapy has a predictive role. A single cycle of HDCT with ASCT, does not improve outcomes and should not be offered as planned therapy. Two or three cycles of HD CE improved survival for refractory or relapsed GCT patients.
